Immune Responders Research Articles

RNA-Seq Analysis of Peripheral Whole Blood from Dairy Bulls with High and Low Antibody-Mediated Immune Responses-A Preliminary Study.

Enhancing the immune response through breeding is regarded as an effective strategy for improving animal health, as dairy cattle identified as high immune responders are reported to have a decreased prevalence of economically significant diseases. The identification of differentially expressed genes (DEGs) associated with immune responses might be an effective tool for breeding healthy dairy cattle. In this study, antibody-mediated immune responses (AMIRs) were induced by the immunization of hen egg white lysozyme (HEWL) in six Chinese Holstein dairy bulls divided into high- and low-AMIR groups based on their HEWL antibody level. Then, RNA-seq was applied to explore the transcriptome of peripheral whole blood between the two comparison groups. As a result, several major upregulated and downregulated genes were identified and attributed to the regulation of locomotion, tissue development, immune response, and detoxification. In addition, the result of the KEGG pathway analysis revealed that most DEGs were enriched in pathways related to disease, inflammation, and immune response, including antigen processing and presentation, Staphylococcus aureus infection, intestinal immune network for IgA production, cytokine-cytokine receptor interaction, and complement and coagulation cascades. Moreover, six genes (BOLA-DQA5, C5, CXCL2, HBA, LTF, and COL1A1) were validated using RT-qPCR, which may provide information for genomic selection in breeding programs. These results broaden the knowledge of the immune response mechanism in dairy bulls, which has strong implications for breeding cattle with an enhanced AMIR.

In HIV-infected patients, intestinal bacteria-derived products interfere with CD4<sup>+</sup>T cell regeneration

Despite successful suppression of viral replication by antiretroviral drugs there is no significant increase in the number of peripheral CD4+T lymphocytes in some HIV-infected patients (immune nonresponse to therapy). One of the crucial factors for immunodeficiency aggravation is immune activation developing in response to the bacterial products entry into the bloodstream through the damaged intestinal barrier. Additionally, the intestinal microflora produces various solutes that accumulate in the blood and exhibit toxic properties. This work aimed to evaluate the effect of intestinal microbial products (para-cresol sulfate and indoxyl sulfate) on the number of CD4+T lymphocytes in HIV-infected patients receiving antiretroviral therapy. The object of the study was the peripheral blood of HIV-infected subjects with different immune system restoration efficiency during the therapy. Uninfected donors were enrolled as healthy controls. Plasma concentrations of IL-6 (p = 0.012), IP-10 (p = 0.0004), and sCD14 (p = 0.003) in HIV-infected immune nonresponders were increased compared with those in individuals with effective restoration of CD4+Tcells (immune responders). Although both groups of HIV-positive subjects did not differ in plasma lipopolysaccharide and I-FABP levels, para-cresol sulfate (p = 0.001) and indoxyl sulfate (p = 0.042) concentrations were increased in immune non-responders. In vitro experiments showed a negative dose-dependent effect of para-cresol sulfate and indoxyl sulfate on the viability and mitotic activity of CD4+T lymphocytes. Thus, in HIV-infected patients with impaired regeneration of CD4+T lymphocytes during antiretroviral therapy, a higher level of systemic inflammation is noted than in subjects responding to treatment with an increase in the number of CD4+T cells. The severity of the intestinal barrier damage and the load of bacterial components released into the bloodstream are approximately the same in HIV-infected individuals with different efficiency of immune recovery in response to treatment. Simultaneously, the blood plasma of immune non-responders is significantly enriched with microbial products of intestinal origin: para-cresol sulfate and indoxyl sulfate. The significant decrease in the proliferative capacity of CD4+T cells stimulated in vitro and the induction of their death in the presence of these toxins may be a reason for the ineffective restoration of the number of CD4+T lymphocytes in HIV-infected individuals receiving antiretroviral therapy.

Improvement of Islet Engrafts via Treg Induction Using Immunomodulating Polymeric Tolerogenic Microparticles.

Type 1 diabetes (T1D) is a life-threatening condition for which islet transplantation offers a way to extend longevity and vastly improve quality of life, but the degree and duration of success can vary greatly due to the patient's protective immunity against foreign material. The field is in need of cellular engineering modalities to promote a localized, tolerogenic environment to protect transplanted islet tissue. Artificial antigen-presenting cells (aAPCs) can be designed exogenously to mimic immune cells, such as dendritic cells, and administered to patients, allowing greater control over T cell differentiation. As regulatory T cell (Treg) modulation can reduce the activity of cytotoxic T-effector populations, this strategy can be used to promote immune acceptance of both biomaterials and cellular transplants, such as islets. A new class of poly(lactic-co-glycolic acid) (PLGA) and PLGA/PBAE-blend aAPCs containing transforming growth factor beta and conjugated with anti-CD3 and anti-CD28 antibodies, called tolerogenic aAPCs (TolAPCs), are specifically designed to generate a tolerogenic response by inducing Tregs. We characterized TolAPCs' physical and chemical properties via advanced particle imaging and sizing modalities and investigated their impact on the local and systemic immune system across BALB/c and C57BL/6 mouse strains as well as healthy male and female mice via histologic, gene expression, and immunofluorescence staining methods. Strain-specific differences were observed, whereas sex made no difference in the TolAPC response. TolAPCs stimulated the expansion of FOXP3+ Tregs and provided islet cell protection, maintaining improved glucose-stimulated insulin secretion in vitro when co-cultured with cytotoxic CD8+ T cells. We also explored the ability of this TolAPC platform to promote tolerance in a streptozotocin-induced murine T1D C57BL/6 mouse model. We achieved partial islet protection over the first few days following co-injection with PLGA/PBAE TolAPCs; however, grafts failed soon thereafter. Analysis of the local injection site demonstrated that other immune cell types, including APCs and cytotoxic natural killer cells, increased in the islet injection site. While we aimed to promote a localized tolerogenic microenvironment in vivo using biodegradable TolAPCs to induce Tregs and extend islet transplant durability, further TolAPC improvements will be required to both elongate efficacy and control additional immune cell responders.

Combination immunotherapy of ibrutinib, fludarabine, and pembrolizumab for high-risk CLL patients: clinical and immunological analysis of a pilot phase II study

Abstract Chronic lymphocytic leukemia (CLL) is due to clonal expansion of CD5+ B cells. Immunosuppression is a hallmark of CLL and includes impaired anti-tumor T cell responses. Exhaustion of PD-1+ CD8 T cells has been implicated in disease progression, providing a rationale to test checkpoint inhibitors in the clinic. However, single-agent anti-PD-1 antibodies lacked clinical efficacy. Here, we analyzed immunologic parameters in patients enrolled on a phase II study of ibrutinib (continuous administration), fludarabine (2 cycles) and pembrolizumab (for 18 cycles after fludarabine). 13 patients were enrolled, 10 patients were evaluable, 9 patients achieved partial response (90%) and 1 patient complete response (10%). Bulk RNA-seq of CLL and T cells revealed inhibition of B-cell receptor and NF-kB signaling in tumor cells, and increased proliferation and activation gene signatures in CD3+ T cells. The proportion of Ki-67+ CD8 T cells increased in 5 out of 13 patients (immune responders) 3 weeks after the first dose of pembrolizumab. Compared with immune non-responders, responders had a significantly higher percentage of CD45RO-CD27+ and CD45RO+CD27+ CD8 T cells. At 6 months, T cell proliferation in all patients was back to baseline and there was no change in TCR clonality at 12 months. In vitro stimulation with CD3 and CD28 antibodies upregulated activation markers on CD8 T cells in all patients, increases in Ki-67 were variable. Overall, responses in patients were weaker than in healthy controls. In summary, pembrolizumab in combination with ibrutinib transiently increased CD8 T cell proliferation in a subset of CLL patients but did not improve the clinical response over ibrutinib.

Abstract 5883: Computational analysis of immune synapses in melanoma tumor microenvironment

Abstract High-resolution multiplexed tissue imaging such as imaging mass cytometry (IMC) has enabled quantitative cell characterization with preserved tissue architecture. However, the subcellular resolution information has not been fully leveraged yet, as most analyses have focused on cellular or compartment level features. Here, we have developed a robust computational approach integrating cellular spatial and molecular features in multiplexed images to quantify immune synapses. Our approach enables computational detection of subcellular enrichment of T cell co-receptors at immune synapses, which are key regulators of T cell functions in the tumor microenvironment (TME). We quantified immune synapse strength between T cells and various antigen-presenting cells in tumor regions in one melanoma whole tissue immunofluorescence dataset and two independent melanoma IMC datasets covering 99 patients. We observed that sub-localizations of immune synapse-related molecules are highly correlated, e.g. CD3 with CD8. These co-localizations are cell type-specific, with differential behaviors in CD4+ or CD8+ T subtypes. Intra-tumoral T-cell-myeloid synapses are associated with improved T cell proliferation (p = 2.8E-4). In addition, we also observed that cytotoxic T cell - melanoma synapses in immune rich regions are stronger in immune checkpoint inhibition therapy responders than in non-responding patients (p = 0.013). Our approach enables computational resolution of spatial inter-cellular interactions within the TME, is applicable across imaging modalities, and facilities assessment of biological and clinical significance. Citation Format: Zichao Liu, Victor G. Wang, Jan Martinek, Ali Foroughi pour, Jie Zhou, Karolina Palucka, Jeffrey H. Chuang. Computational analysis of immune synapses in melanoma tumor microenvironment [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5883.

Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes

Plasmacytoid dendritic cells (pDCs) sense viral and bacterial products through Toll-like receptor (TLR)-7 and-9 and translate this sensing into Interferon-α (IFN-α) production and T-cell activation. The understanding of the mechanisms involved in pDCs stimulation may contribute to HIV-cure immunotherapeutic strategies. The objective of the present study was to characterize the immunomodulatory effects of TLR agonist stimulations in several HIV-1 disease progression phenotypes and in non HIV-1 infected donors. pDCs, CD4 and CD8 T-cells were isolated from 450ml of whole blood from non HIV-1 infected donors, immune responders (IR), immune non responders (INR), viremic (VIR) and elite controller (EC) participants. pDCs were stimulated overnight with AT-2, CpG-A, CpG-C and GS-9620 or no stimuli. After that, pDCs were co-cultured with autologous CD4 or CD8 T-cells and with/without HIV-1 (Gag peptide pool) or SEB (Staphylococcal Enterotoxin B). Cytokine array, gene expression and deep immunophenotyping were assayed. pDCs showed an increase of activation markers levels, interferon related genes, HIV-1 restriction factors and cytokines levels after TLR stimulation in the different HIV-disease progression phenotypes. This pDC activation was prominent with CpG-C and GS-9620 and induced an increase of HIV-specific T-cell response even in VIR and INR comparable with EC. This HIV-1 specific T-cell response was associated with the upregulation of HIV-1 restriction factors and IFN-α production by pDC. These results shed light on the mechanisms associated with TLR-specific pDCs stimulation associated with the induction of a T-cell mediated antiviral response which is essential for HIV-1 eradication strategies. This work was supported by Gilead fellowship program, the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, "a way to make Europe") and the Red Temática de Investigación Cooperativa en SIDA and by the Spanish National Research Council (CSIC).

Microglial IL-1RA ameliorates brain injury after ischemic stroke by inhibiting astrocytic CXCL1-mediated neutrophil recruitment and microvessel occlusion.

Acute ischemic stroke (AIS), one of the leading causes of mortality worldwide, is characterized by a rapid inflammatory cascade resulting in exacerbation of ischemic brain injury. Microglia are the first immune responders. However, the role of postischemic microglial activity in ischemic brain injury remains far from being fully understood. Here, using the transgenic mouse line CX3 CR1creER :R26iDTR to genetically ablate microglia, we showed that microglial deletion exaggerated ischemic brain injury. Associated with this worse outcome, there were increased neutrophil recruitment, microvessel blockade and blood flow stagnation in the acute phase, accompanied by transcriptional upregulation of chemokine (C-X-C motif) ligand 1 (CXCL1). Our study showed that microglial interleukin-1 receptor antagonist (IL-1RA) suppressed astrocytic CXCL1 expression induced by oxygen and glucose deprivation and inhibited neutrophil migration. Furthermore, neutralizing antibody therapy against CXCL1 or the administration of recombinant IL-1RA protein reduced brain infarct volume and improved motor coordination performance of mice after ischemic stroke. Our study suggests that microglia protect against acute ischemic brain injury by secreting IL-1RA to inhibit astrocytic CXCL1 expression, which reduces neutrophil recruitment and neutrophil-derived microvessel occlusion.

CD8+ T-cell immunity orchestrated by iNKT cells.

CD8+ T cells belonging to the adaptive immune system play key roles in defendingagainst viral infections and cancers. The current CD8+ T cell-based immunotherapy has emerged as a superior therapeutic avenue for the eradication of tumor cells and long-term prevention of their recurrence in hematologic malignancies. It is believed that an effective adaptive immune response critically relies on the help of the innate compartment. Invariant natural killer T (iNKT) cells are innate-like T lymphocytes that have been considered some of the first cells to respond to infections and can secrete a large amount of diverse cytokines and chemokines to widely modulate the innate and adaptive immune responders. Like CD8+ T cells, iNKT cells also play an important role in defense against intracellular pathogenic infections and cancers. In this review, we will discuss the CD8+ T-cell immunity contributed by iNKT cells, including iNKT cell-mediated cross-priming and memory formation, and discuss recent advances in our understanding of the mechanisms underlying memory CD8+ T-cell differentiation, as well as aging-induced impairment of T-cell immunity.

Abstract IA016: Lessons learned from clinical trials of MUC1 peptide vaccines for cancer prevention

Abstract We report on three trials of a MUC1 peptide vaccine for cancer prevention. Two trials were pilot studies evaluating vaccine immunogenicity and safety. One was in subjects with advanced colon adenomas, and the other in smokers at risk for lung cancer. The third trial was a multi-center, randomized placebo-controlled trial in subjects with advanced adenoma that included an assessment of the clinical efficacy of the vaccine to prevent recurrent adenoma. All trials successfully recruited their full complement of participants and the vaccine was well tolerated with no safety concerns. The response rate in the colon adenoma trials was 43% in the pilot study and 25% in the placebo- controlled multicenter trial. Only 10% of smokers responded to the vaccine. Higher levels of circulating myeloid derived suppressor cells (MDSC) were consistently associated with the lack of an immune response. This suggests that even in pre-malignancy immunosuppressive tendencies can impair vaccine immunogenicity. Responders to the vaccine demonstrated immune memory at one year. In the multicenter adenoma trial that evaluated the efficacy of the vaccine on adenoma recurrence, immune responders demonstrated an association with a reduced rate of adenoma recurrence. In future studies, patient selection based on circulating MDSC levels, or concomitant use of agents to counter MDSC immunosuppressive function or otherwise improve T cell function, should be considered. Citation Format: Robert E. Schoen. Lessons learned from clinical trials of MUC1 peptide vaccines for cancer prevention [abstract]. In: Proceedings of the Second Biennial NCI Meeting: Translational Advances in Cancer Prevention Agent Development (TACPAD); 2022 Sep 7-9. Philadelphia (PA): AACR; Can Prev Res 2022;15(12 Suppl_2): Abstract nr IA016.

Subcellular location of source proteins improves prediction of neoantigens for immunotherapy

Antigen presentation via the major histocompatibility complex (MHC) is essential for anti‐tumor immunity. However, the rules that determine which tumor‐derived peptides will be immunogenic are still incompletely understood. Here, we investigated whether constraints on peptide accessibility to the MHC due to protein subcellular location are associated with peptide immunogenicity potential. Analyzing over 380,000 peptides from studies of MHC presentation and peptide immunogenicity, we find clear spatial biases in both eluted and immunogenic peptides. We find that including parent protein location improves the prediction of peptide immunogenicity in multiple datasets. In human immunotherapy cohorts, the location was associated with a neoantigen vaccination response, and immune checkpoint blockade responders generally had a higher burden of neopeptides from accessible locations. We conclude that protein subcellular location adds important information for optimizing cancer immunotherapies.

Single-cell sequencing resolves the landscape of immune cells and regulatory mechanisms in HIV-infected immune non-responders

Immune non-responder after highly active antiretroviral therapy (HAART) is the main cause of opportunistic infections and high mortality in AIDS patients, but the mechanism underlying immune reconstitution failure is poorly understood. Here, we performed scRNA-seq, and scATAC-seq analysis of peripheral blood mononuclear cells (PBMCs) derived from immune non-responder (INR) and responder (IR) HIV-1-infected subjects. We found low expression of mucosal-associated invariant T (MAIT) cells in INRs, which exhibited transcriptional profiles associated with impaired mitochondrial function and apoptosis signaling. Single-cell assays for transposase-accessible chromatin (scATAC-seq) and flow cytometry revealed diminished mitochondrial fitness in MAIT cells from INRs, and MAIT had low expression of transcription factor A for mitochondria (TFAM) and peroxisomal proliferator-activated receptor alpha (PPARA). These findings demonstrate that restoring mitochondrial function could modulate the immune dysfunction characteristic of MAIT against bacterial co-infections in INRs subjects.

149 Differences in Gene Expression Following Natural Exposure to Gastrointestinal Parasites between Sheep Selected for High Innate Responses and High Antibody-Mediated Adaptive Immune Responses

Abstract Parasitism by gastrointestinal nematodes (GINs) is a major source of morbidity and mortality for sheep flocks grazed on pasture. Since there is evidence for genetic resistance to GINs in some sheep breeds, genetic selection for immunologic resistance to GIN is a possible management strategy. This study sought to identify differences at the transcriptome level between Ridau-Arcott sheep characterized as high innate immune responders (IIRs, n=5) or high antibody-mediated immune responders (AbMIRs, n=5) following natural exposure to and infection with GINs after spending the summer on GIN-infested pasture; infection was confirmed with individual fecal egg counts. The transcriptomes of the high IIR and high AbMIR animals were also compared with GIN-naïve sheep of the same breed (all medium IIR and AbMIR responders, n = 7). Liver tissue samples from the 17 animals were used to perform transcriptomic analyses using RNA-Sequencing technology. The CLC Genomics Workbench 20.0.4 (CLC Bio, Aarhaus, Denmark) software was used to map reads to the most recent ovine reference genome (Oar rambouillet.v1.0.105), and for differential gene expression analysis. In total, 144 differentially expressed genes (DEG) were found between the high IIRs and the high AbMIRs (FDR< 0.05, and fold change (FC) abs > 2). When compared to the naïve animals, 136 and 53 DEG were found between them and the high IIRs and the high AbMIRs, respectively. In order to verify their function in the host immune response to GINs, functional enrichment analyses were performed on these candidate genes using the AmiGO2 software. Monocarboxilic acid metabolism was identified as an enriched biological process (FDR < 0.05), and ammonia-lyase activity and metalloendopeptidase activity were enriched molecular functions between the high IIR and high AbMIR animals (FDR < 0.05). These preliminary results improve understanding of how host resistance to GINs is genetically regulated through the innate and adaptive immune systems in sheep.

Conglomeration of T- and B-Cell Matrix Responses Determines the Potency of Human Bone Marrow Mesenchymal Stromal Cells.

Cell manufacturing facilities need to define the potency of mesenchymal stromal cells (MSCs) as cellular therapeutics in advanced clinical trials or marketing approval. Since MSCs' mechanism of action in humans is not well defined, more than a single functional property of MSCs needs to be captured as a surrogate measure of potency utilizing assay matrix technologies. However, the current limitation is the sole investigation of MSC-mediated T-cell suppression as a surrogate measure of potency. We investigated the effect of MSCs on B-cell matrix responses to be incorporated into the assay matrix potency analytical system. Our results demonstrate that MSCs inhibit B-cell differentiation and block pan-antibody secretion upon activation of B cells in the PBMCs. In contrast, MSCs are inferior in blocking B-cell matrix responses when purified B cells are used. Mechanistic analysis has demonstrated that MSC-mediated inhibition of B-cell matrix responses is non-contact dependent and Tryptophan metabolic pathway plays a major role, akin to the mechanism of MSC-mediated T-cell suppression. MSCs also inhibit both T-cell and B-cell responses when both of these lymphoid populations are concurrently activated in the PBMCs. Secretome analysis of MSC and T/B cell-activated PBMC cocultures identified direct and inverse correlative matrix signatures between humoral antibody isotypes and secretory molecules. The current analysis of the combined and concomitant investigation of T-cell and B-cell matrix responses fulfills the potency assay matrix strategy by incorporating MSCs' interaction with more than a single inflammatory immune responder.

Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy.

Glioblastoma multiforme (GBM) remains incurable despite aggressive implementation of multimodal treatments after surgical debulking. Almost all patients with GBM relapse within a narrow margin around the initial resected lesion due to postsurgery residual glioma stem cells (GSCs). Tracking and eradicating postsurgery residual GSCs is critical for preventing postoperative relapse of this devastating disease, yet effective strategies remain elusive. Here, we report a cavity-injectable nanoporter-hydrogel superstructure that creates GSC-specific chimeric antigen receptor (CAR) macrophages/microglia (MΦs) surrounding the cavity to prevent GBM relapse. Specifically, we demonstrate that the CAR gene-laden nanoporter in the hydrogel can introduce GSC-targeted CAR genes into MΦ nuclei after intracavity delivery to generate CAR-MΦs in mouse models of GBM. These CAR-MΦs were able to seek and engulf GSCs and clear residual GSCs by stimulating an adaptive antitumor immune response in the tumor microenvironment and prevented postoperative glioma relapse by inducing long-term antitumor immunity in mice. In an orthotopic patient-derived glioblastoma humanized mouse model, the combined treatment with nanoporter-hydrogel superstructure and CD47 antibody increased the frequency of positive immune responding cells and suppressed the negative immune regulating cells, conferring a robust tumoricidal immunity surrounding the postsurgical cavity and inhibiting postoperative glioblastoma relapse. Therefore, our work establishes a locoregional treatment strategy for priming cancer stem cell-specific tumoricidal immunity with broad application in patients suffering from recurrent malignancies.

Natural killer cell exhaustion in SARS-CoV-2 infection.

At the end of 2019, an outbreak of a severe respiratory disease occurred in Wuhan China, and an increase in cases of unknown pneumonia was alerted. In January 2020, a new coronavirus named SARS-CoV-2 was identified as the cause. The virus spreads primarily through the respiratory tract, and lymphopenia and cytokine storms have been observed in severely ill patients. This suggests the existence of an immune dysregulation as an accompanying event during a serious illness caused by this virus. Natural killer (NK) cells are innate immune responders, critical for virus shedding and immunomodulation. Despite its importance in viral infections, the contribution of NK cells in the fight against SARS-CoV-2 has yet to be deciphered. Different studies in patients with COVID-19 suggest a significant reduction in the number and function of NK cells due to their exhaustion. In this review, we summarize the current understanding of how NK cells respond to SARS-CoV-2 infection.

Gut-derived bacterial toxins impair memory CD4+ T cell mitochondrial function in HIV-1 infection.

People living with HIV (PLWH) who are immune nonresponders (INRs) are at greater risk of comorbidity and mortality than are immune responders (IRs) who restore their CD4+ T cell count after antiretroviral therapy (ART). INRs have low CD4+ T cell counts (<350 c/μL), heightened systemic inflammation, and increased CD4+ T cell cycling (Ki67+). Here, we report the findings that memory CD4+ T cells and plasma samples of INRs from several cohorts are enriched in gut-derived bacterial solutes p-cresol sulfate (PCS) and indoxyl sulfate (IS) that both negatively correlated with CD4+ T cell counts. In vitro PCS or IS blocked CD4+ T cell proliferation, induced apoptosis, and diminished the expression of mitochondrial proteins. Electron microscopy imaging revealed perturbations of mitochondrial networks similar to those found in INRs following incubation of healthy memory CD4+ T cells with PCS. Using bacterial 16S rDNA, INR stool samples were found enriched in proteolytic bacterial genera that metabolize tyrosine and phenylalanine to produce PCS. We propose that toxic solutes from the gut bacterial flora may impair CD4+ T cell recovery during ART and may contribute to CD4+ T cell lymphopenia characteristic of INRs.

OC-0265 Using proton radiation or OXi4503 to convert non-immunogenic tumours into immune responders

OC-0265 Using proton radiation or OXi4503 to convert non-immunogenic tumours into immune responders

Neuroimmunomodulatory balance between pro and anti‐inflammatory cytokines regulate m‐CoV induced alteration of gap junction protein Cx43

Mouse hepatitis virus (MHV), a murine β‐CoV, is an experimental model used to understand the viral‐induced acute neuroinflammation and chronic progressive demyelination, which are the characteristic hallmarks of the human neurological disease Multiple Sclerosis. MHV induced neuroinflammation provides an excellent cause‐effective platform to understand how the virus can initiate neuroinflammation by causing direct neuroglial cell dystrophy, leading to chronic progressive myelin damage with or without concurrent axonal loss. Previous studies have postulated that a significant nexus between host proteins is also involved in regulating host response to viral replication. One such protein is a transmembrane protein connexin 43 (Cx43) belonging to the gap junction family. Cx43 is one of the most abundant gap junction proteins in astrocytes responsible for metabolic coupling with other CNS cells to maintain homeostasis. MHV infection in mice results in a significant decrease in the expression of Cx43 during the acute stage (day 5‐6) of MHV infection when viral titer reaches its peak and the brain presents with acute encephalitis characterized by perivascular cuffing and microglial nodule formation. Surprisingly, Cx43 returns to normal levels as infectious viral particles go below the detection limit by day 10 p.i. which marks the transition of innate immune responses to adaptive immunity. Interestingly, this reduced expression of Cx43 at Day 5 accords with increased pro‐inflammatory cytokines, oxidative stress, and activation of UPR pathway proteins. This study investigated the transcriptional regulation of TNF‐α, Il‐6, IL‐10, IL‐1β and TGF‐β in the alteration of Cx43 expression and trafficking during day 5/6 and day 10 post MHV infection. TNF‐α, IL‐10, IL‐6,IL‐1β are the major inflammatory cytokines upregulated during the acute stage of MHV infection (5‐6 p.i.). Additionally, TNF‐α and IL‐1β are known to be negative regulators of Cx43 expression and could be attributed to the decrease in Cx43 observed in our studies. Furthermore, our studies also revealed that in MHV infection, apart from the very high expression of IL‐10 another anti‐inflammatory cytokine TGF‐β expression increases when proinflammatory milieu of cytokines shifts towards the anti‐inflammatory condition in the inflamed brain. As TGF‐β is a positive regulator of Cx43, it may be responsible for the restoration of Cx43 expression and its trafficking to the cell surface resulting in functional gap junctional communication. This re‐establishment of intercellular communication maybe essential to bring back the homeostasis in the inflamed brain. The balance between pro‐inflammatory cytokines and the anti‐inflammatory mediators may regulate the host response to counteract the viral infection by altering the gap junctional communication. This study thus presents crucial evidence to support the nexus between immune inflammatory mediators and host regulatory responders in MHV induced neuroinflammation.

PD-1 agonist modulates ILC2 metabolism and ameliorates airway hyperreactivity

Abstract Allergic asthma is a chronic inflammatory disease characterized by airway hyperreactivity (AHR) and type-2 immune response. Type-2 innate lymphoid cells (ILC2s) mimic T helper 2 (Th2) cells in cytokine secretion and are among the first pulmonary immune responders to the allergen-induced alarmins. Programmed cell death protein-1 (PD-1) is known as an immune checkpoint equipped with tyrosine-based inhibitory motifs in the cytoplasmic tail. Since PD-1 is associated with immune regulation in many inflammatory diseases, the objective of this study was to investigate the role of PD-1 in the initiation and development of AHR. Lung function tests, RNA sequencing, flow cytometry, targeted metabolomic assays, and adoptive transfer experiments were principally used to explore the role of PD-1 in AHR mouse models and in human ILC2s. Using IL-33 and Alternaria alternata models, we have demonstrated that PD-1 knockout mice develop a higher AHR and lung inflammation as compared to control wild-type mice. In particular, PD-1 is highly inducible on lung ILC2s and downregulates their effector functions. Moreover, PD-1 controls glycolysis and methionine catabolism, limiting, therefore, the proliferation of activated pulmonary ILC2s. In line with mice data, PD-1 is inducible and functional in human ILC2s in response to IL-33. To confirm the translational relevance of our findings, we tested a novel human PD-1 agonist in vitro and in a humanized mouse model of AHR. Interestingly, the PD-1 agonist decreases human ILC2 activation and is able to dampen AHR and lung inflammation. Altogether this study reveals the protective role of PD-1 as regulators of ILC2s and highlights for the first time the therapeutic potential of PD-1 agonists in allergic asthma. Supported by grants from NIH: R01 ES025786, R01 ES021801, R01 HL144790, and R21 AI109059 (O.A.)

Sialylation of CD11b/CD18 regulates Neutrophil Transepithelial Migration and Neutrophil Inflammatory function in the Intestine

Neutrophils (PMNs) are the first immune responders to infection/inflammation playing critical roles in clearing invading microbes and promoting tissue repair. However, dysregulated trafficking of PMNs across mucosal surfaces is a pathological hallmark of diseases characterized by persistent or intermittent bursts of inflammation including inflammatory bowel disease (IBD). The critical final step in PMN trafficking into mucosal lined organs (including the gut) involves transepithelial migration (TEpM). The glycoprotein CD11b/CD18 is the predominant β2 integrin mediating PMN TEpM into the intestinal lumen. Furthermore, CD11b/CD18 also regulates key PMN inflammatory effector functions that are implicated in IBD pathogenesis including superoxide release. We have previously demonstrated that specific GlcNAc and Lewis X glycan structures on CD11b/CD18 can be targeted to reduce PMN intestinal trafficking. Recent mass spectrometry analyses revealed the presence of specific sialylated glycan structures on PMN CD11b. However the role of sialylation in regulating PMN CD11b/CD18 function is not well understood. Using lectins recognizing the most common linkages of sialic acid we show that sialidase mediated removal of α2‐3 sialic acid from CD11b/CD18 occurs during PMN migration across intestinal epithelia. Furthermore, specific inhibition of sialidase activity was found to reduce PMN intestinal migration in vitro and in vivo. In addition to limiting PMN intestinal trafficking, sialidase inhibition also reduced key PMN effector functions including degranulation and superoxide release. Finally, we demonstrate that sialidase inhibition impedes PMN CD11b activation and blocks downstream β2 integrin signaling mediated by Spleen tyrosine kinase (Syk). Therefore α2‐3 sialylated glycans on CD11b/CD18 represent novel targets for ameliorating PMN mediated intestinal tissue damage and reducing mucosal inflammation in IBD.